Angiogenesis inhibitors in cancer therapy

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 667-674

  Dredge, Keith ^a   Dalgleish, Angus G ^a   Marriott, J Blake ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Angiogenesis inhibitors; Cancer; Cytotoxic agents

Indexed keywords

2 METHOXYESTRADIOL; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ADENOVIRUS VECTOR; ADVEXIN; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BTO 956; CC 1069; CETUXIMAB; CYTOTOXIC AGENT; DOCETAXEL; ENDOSTATIN; ENMD 0995; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; IM 862; LENALIDOMIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL POLIGLUMEX; PI 88; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TEMOZOLOMIDE; TEMPOSTATIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THROMBOSPONDIN 1; THROMBOSPONDIN 2; THYMIDINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; ZOLEDRONIC ACID;

CANCER; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; GENE THERAPY; HEPES SIMPLEX VIRUS VECTOR; HUMAN; LOW DRUG DOSE; NONHUMAN; REVIEW; SIDE EFFECT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0042165850     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. N Eng J Med (1971) 285(21):1182-1186. Seminal article suggesting a role for angiogenesis in cancer.
2. Dredge K, Dalgleish AG, Marriott JB: Recent developments in antiangiogenic therapy. Expert Opin Biol Ther (2002) 2(8):953-966.
3. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2002) 100(1):57-70.
4. Bouck N, Stellmach V, Hsu SC: How tumors become angiogenic. Adv Cancer Res (1996) 69:135-174.
5. Pruneri G, Ponzoni M, Ferreri AJM, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A et al: Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol (2002) 118(3):817-820.
6. Kakimoto T, Hattori Y, Okamoto S, Sato N, Kamata T, Yamaguchi M, Morita K, Yamata T, Takayama N, Uchida H, Shimada N et al: Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res (2002) 93(9):1029-1036.
7. Liekens S, De Clercq E, Neyts J: Angiogenesis: Regulators and clinical applications. Biochem Pharmacol (2001) 61(3):253-270. Comprehensive review of the regulators involved in angiogenesis, highlighting a number of clinically applicable angiogenesis inhibitors.
8. Jeong SJ, Higuchi R, Miyamoto T, Ono M, Kuwano M, Mawatari SF: Bryoanthrathiophene, a new antiangiogenic constituent from the bryozoan Watersipora subtorquata (d'Orbigny, 1852). J Nat Prod (2002) 65(9):1344-1345.
9. Dabrosi C, Chen J, Wang L, Thompson LU: Flaxseed inhibits metastasis and decreases vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett (2002) 185(1):31-37.
10. Roy S, Khanna S, Alessio HM, Vider J, Bagchi D, Bagchi M, Sen CK: Anti-angiogenic property of edible berries. Free Radical Res (2002) 36(9):1023-1031.
11. Miao RQ, Agata J, Chao L, Chao J: Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood (2002) 100(9):3245-3252.
12. Gururaj AE, Belakavadi M, Venkatesh DA, Marme D, Salimath BP: Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Comm (2002) 297(4):934-942.
13. Shim JS, Kim DH, Jung HJ, Kim JH, Lim D, Lee SK, Kim KW, Ahn JW, Yoo JS, Rho JR, Shin J, Kwon HJ: Hydrazinocurcumin, a novel synthetic curcumin derivative, is a potent inhibitor of endothelial cell proliferation. Bioorg Med Chem (2002) 10(9):2987-2992.
14. Zhou JR, Yu LY, Zhong Y, Nassr RL, Franke AA, Gaston SM, Blackburn GL: Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. Prostate (2002) 53(2):143-153.
15. Zhang L, Rui YC, Yang PY, Qiu Y, Li TJ, Liu HC: Inhibitory effects of Ginkgo biloba extract on vascular endothelial growth factor in rat aortic endothelial cells. Acta Pharm Sinica (2002) 23(10):919-923.
16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315-328. First report that primary tumor growth and metastases suppression in the Lewis lung carcinoma model can be mediated by angiostatin.
17. Sim BK, MacDonald NJ, Gubish ER: Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev (2000) 19(1-2):181-190.
18. Kisker O, Becker CM, Prox D, Fannon M, D'Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J: Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res (2001) 61(20):7669-7674. Soluble endostatin administered continuously into the peritoneal cavity by a mini-osmotic pump is 50% more effective in tumor suppression than the equivalent administered intraperitoneally. The authors also found that a 10-fold lower dose administered by this method was as good as the intraperitoneal schedule.
19. Matter A: Tumor angiogenesis as a therapeutic target. Drug Disc Today (2001) 6(19):1005-1024.
20. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2): 277-285. Results from this study indicate that a murine hemangioendothelioma produces a novel and specific inhibitor (endostatin) of endothelial cell proliferation in vitro and potent inhibitor of angiogenesis and tumor growth in vivo.
21. Li WW, Li VW, Brainerd N, Fagen SJ: Global development of angiogenesis inhibitors for cancer: Principles, progress and new paradigms. Jpn J Cancer Chemother (2002) 29(Suppl 1):50-58.
22. Phase II endostatin clinical trial to begin in People's Republic of China: Clinical updates-oncology. Angiogenesis Foundation, Cambridge, MA, USA (2002). http://www.angio.org
23. Vailhe B, Feige JJ: Thrombospondins as anti-angiogenic therapeutic agents. Curr Pharm Des (2003) 9(7):583-588.
24. min/+ mouse model. Carcinogenesis (2003) 24(2):199-207.
25. Hawighorst T, Oura H, Streit M, Janes L, Nguyen L, Brown LF, Oliver G, Jackson DG, Detmar M: Thrombospondin-1 selectively inhibits early stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene (2002) 21(52):7945-7956.
26. Rak J, Kerbal RS: bFGF and tumor angiogenesis - Back in the limelight? Nat Med (1997) 3(10):1083-1084.
27. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res (2002) 62(16):4645-4655.
28. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 62(24):7284-7290.
29. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, Yamada Y, Cherrington J, McMahon G, Shibuya M, Kuwano M, Ono M: Antiangiogenic effect of SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther (2002) 1(5):295-302.
30. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999 59(21):5412-5416.
31. Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM: SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB (2002) 16(7):681-690.
32. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A: Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res (2002) 8(9):2798-2805.
33. Fogarty M: Learning from angiogenesis trial failures. The Scientist (2002) 18:31-33.
34. Lamy S, Gingras D, Beliveau R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res (2002) 62(2):381-385.
35. Kondo T, Ohta T, Igura K, Hara Y, Kaji K: Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cells growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett (2002) 180(2):139-144.
36. Cao Y, Cao R: Angiogenesis inhibited by drinking tea. Nature (1999) 398(6726):381.
37. Boivin D, Gendron S, Beaulieu E, Gingras D, Beliveau R: The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther (2002) 1(10):795-802.
38. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science (2002) 295(5564):2387-2392.
39. Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA: Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol (2002) 20(5):1383-1388. Clinical trial combining temozolomide and marimastat in glioblastoma multiforme. Progression-free survival at 6 months that exceeded the literature by 29% was observed and phase II study criteria were met.
40. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ et al: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res (2002) 62(20):5720-5726.
41. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A: Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer (2002) 101(6):567-575.
42. Sorbera LA, Leeson PA, Bayes M: Bevacizumab-oncolytic. Drugs Future (2002) 27:625-632.
43. Pulkkanen KJ, Laukkanen JM, Fuxe J, Kettunen MI, Rehn M, Kannasto JM, Parkkinen JJ, Kauppinen RA, Petterson RF, Yla-Herttuala S: The combination of HSV-tk and endostatin gene therapy eradicated orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther (2002) 9(11):908-916.
44. Nakashima Y, Yano M, Kobayashi Y, Moriyama S, Sasaki H, Toyama T, Yamashita H, Fukai I, Iwase H, Yamakawa Y, Fujii Y: Endostatin gene therapy on murine lung metastases model utilizing cationic vector mediated intravenous gene delivery. Gene Ther (2003) 10(2):123-130. The authors found that a combination of endostatin gene therapy, using cationic vector-mediated intravenous gene transfer may be a feasible strategy for prevention of disseminated cancers.
45. Ciccolini J, Cuq P, Evrard A, Giacometti S, Pelegrin A, Aubert C, Cano JP, Iliadis A: Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther (2001) 1(2):133-139.
46. Spurbeck WW, Ng CYC, Strom TS, Vanin EF, Davidoff AM: Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood (2002) 100(9):3361-3368.
47. Streit M, Stephen AE, Hawighorst T, Matsuda K, Lange-Asschenfeldt B, Brown LF, Vacanti JP, Detmar M: Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. Cancer Res (2002) 62(7):2004-2012.
48. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): Association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther (2002) 1(13):1191-1200.
49. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 60(7):1878-1886. Details a series of mouse experiments which demonstrate that the common chemotherapeutic agent cyclophosphamide has an anti-angiogenic component alone and antitumor effects can be enhanced by combination with established angiogenesis inhibitor such as TNP-470.
50. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest (2000) 105(8):1045-1047.
51. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS: Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res (2002) 8(1):221-232.
52. Svensson A, Backman U, Jonsson E, Larsson R, Christofferson R: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res (2002) 51(5):607-611.
53. Wietrzyk J, Boratynski J, Grynkiewicz G, Ryczynski A, Radzikowski C, Opolski A: Antiangiogenic and antitumor effects in vivo of genistein applied alone or combined with cyclophosphamide. Anticancer Res (2001) 21(6A):3893-3896.
54. Te Velde EA, Vogten JM, Gebbink MF, VanGorp JM, Voest EE, Borel Rinkes IH: Enhanced antitumor efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg (2002) 89(10):1302-1309.
55. Yamamoto A, Yano S, Shiraga M, Ogawa H, Goto H, Miki T, Zhang H, Sone S: A third generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice. Int J Cancer (2003) 103(6):822-828.
56. Guo Y, Mazar AP, Lebrun JJ, Rabbani SA: An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res (2002) 62(16):4678-4684.
57. Dabrowska-Iwanicka A, Olszewska D, Jalili A, Makowski M, Grzela T, Marczak M, Hoser G, Giermasz A, Golab J, Jakobisiak M: Augmented antitumor effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. J Cancer Res Clin Oncol (2002) 128(8):433-442.
58. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T: Docetaxel enhances the therapeutic effects of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res (2003) 9(2):886-899. Report of a recent study, which demonstrated the enhanced inhibitory effects of the chemotherapeutic agent docetaxel, in conjunction with TNP-470 on tumor growth. Complete response rates up to 57% were observed in non-established and established human TCC tumors.
59. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA (1994) 91(9):4082-4085. This paper presents evidence that thalidomide possesses anti-angiogenic activity in vivo in the rabbit cornea micropocket assay and raises the argument for its use in diseases dependent on angiogenesis.
60. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res (1997) 64(6):971-978.
61. Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol (1998) 55(11):1827-1834.
62. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D: Thalidomide and a thalidomide analog inhibit endothelial cell proliferation in vitro. J Neuro Oncol (1999) 43(2):109-114.
63. Dredge K, Marriott JB, Macdonald CD, Man H-W, Chen R, Muller GW, Stirling D, Dalgleish AG: Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 87(10):1166-1172. This paper presents evidence to demonstrate that some novel thalidomide analogs are more potent anti-angiogenic agents than thalidomide in vitro, and show significant antitumor effect in vivo.
64. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med (1999) 341(21):1565-1571. Significant evidence that thalidomide is active against advanced myeloma, including those who relapse after high-dose chemotherapy is presented.
65. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol (1999) 163(1):380-386.
66. Marriott JB, Muller G, Stirling D, Dalgleish AG: Immunotherapeutic and antitumor potential of thalidomide analogues. Expert Opin Biol Ther (2001) 1(4):675-682.
67. Interim results of phase I/II trial of Actimid for multiple myeloma: Clinical updates-oncology. Angiogenesis Foundation, Cambridge, MA, USA (2002). http://www.angio.org
68. Marriott JB, Clarke IA, Dredge K, Pandha H, Kristaleit H, Muller GW, Stirling D, Dalgleish AG: Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation. Br J Cancer (2002) 86:Abs S26-S26.
69. Schey SA, Jones RW, Raj K, Streetley M: A phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide, in relapsed/refractory multiple myeloma. Abstr Exp Haematol (2002) 30:Abs 280.
70. Celgene announces first target indication for ACTIMID™. Celgene Corporation, Warren, NJ, USA (2003). http://www.celgene.com
71. Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A, Garbisa S, Sartor L, Sava G: Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A. Br J Cancer (2002) 86(6):993-998.
72. Liekens S, Bilsen F, De Clercq E, Priego EM, Camarasa MJ, Perez-Perez MJ, Balzarini J: Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase. FEBS Lett (2002) 510(1-2):83-88.
73. Klein RS, Lenzi M, Lim TH, Hotchkiss KA, Wilson P, Schwartz EL: Novel 6-substituted uracil analogs as inhibitors of the angiogenic actions of thymidine phosphorylase. Biochem Pharmacol (2001) 62(9):1257-1263.
74. Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, Dewhirst MW: The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin Cancer Res (2001) 7(8):2590-2596.
75. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther (2002) 302(3):1055-1061.
76. Presta M, Leali D, Stabile H, Ronca R, Camozzi M, Coco L, Moroni E, Liekens S, Rusnati M: Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des (2003) 9(7):553-566.